Pembrolizumab maintenance after enfortumab vedotin/pembrolizumab induction in front-line metastatic urothelial carcinoma

The Defense Health Agency (DHA) awarded The Institute For Cancer Research a $1,959,353 project grant effective September 1, 2025 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). This award supports clinical research investigating pembrolizumab maintenance therapy following enfortumab vedotin/pembrolizumab induction treatment in front-line metastatic urothelial carcinoma. The research will be conducted at the awardee's facility in Philadelphia, Pennsylvania, with the objective of evaluating therapeutic strategies and generating clinical evidence to advance cancer treatment outcomes for military service members and the broader American public.

As a non-profit cancer research organization, The Institute For Cancer Research will deliver research and development services, clinical trial execution, and translational research activities focused on optimizing immunotherapy combinations for urothelial cancer treatment. This award aligns with the Military Medical Research and Development program's mission to support hypothesis-driven biomedical research addressing critical health challenges through innovative medical solutions, with particular emphasis on cancer immunotherapy and precision medicine approaches.